Primary Treatment: Combination of Oregovomab and Niraparib · No Placebo Group · Phase 2
Combination of Oregovomab and NiraparibExperimental Group · 2 Interventions: Oregovomab, Niraparib · Intervention Types: Biological, Drug
Drug Approval Stage
How many patients have taken this drug
Completed Phase 2
Completed Phase 2
Screening: ~3 weeks
Reporting: baseline up to two years
Closest Location: Duke Cancer Center · Durham, NC
2013First Recorded Clinical Trial
1 TrialsResearching Recurrent Epithelial Cancer of Ovary
34 CompletedClinical Trials
Age 18+ · Female Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
You have recurrent epithelial adenocarcinoma of the ovary, fallopian tube or peritoneum.
You have a performance status of 0, 1 or 2.
You have previously received up to 3 prior lines of therapy, including at least one platinum-based therapy
You have had an elevated serum CA125 level measured at screening within 28 days of start of study treatment.
You have measurable disease, including identification of marker lesions, by radiographic or physical criteria suitable for evaluation according to RECIST v1.1 for documentation of disease response or progression.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.